Affimed N.V. AFMD
0.18 USD 0.00 (+0.00%)
At closeMar 12, 2026, 4:00 PM EDT
0.1815 Day range 0.1815
1.14 52-week range 8.95
- YTD
- 0.00%
- 1 year
- 0.00%
News
benzinga.com Dow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings 
benzinga.com Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket 
benzinga.com US Stocks Edge Higher; Consumer Sentiment Falls In May 
globenewswire.com Affimed Announces Receipt of Nasdaq Delisting Notice MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
benzinga.com Crude Oil Gains 3%; US Inflation Eases In April 
benzinga.com This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday 
globenewswire.com Affimed Announces Filing for the Opening of Insolvency Proceedings MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today…
benzinga.com Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday 
https://www.marketscreener.com Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to…
globenewswire.com Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
globenewswire.com Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their…
globenewswire.com Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
globenewswire.com Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
globenewswire.com Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their…
globenewswire.com Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
globenewswire.com Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
globenewswire.com Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
zacks.com AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy The FDA bestows a Regenerative Medicine Advanced Therapy tag to Affimed's acimtamig in combination with AlloNK for treating Hodgkin lymphoma. Shares fall.
globenewswire.com Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory…
seekingalpha.com Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript Affimed N.V. (NASDAQ:AFMD ) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations & Director of Investor Relations Shawn…
globenewswire.com Affimed Reports Third Quarter 2024 Financial Results & Business Update MANNHEIM, Germany, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
benzinga.com Earnings Scheduled For November 14, 2024 
globenewswire.com Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
globenewswire.com Affimed to Present at the Cantor Global Healthcare Conference 2024 MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their…
seekingalpha.com Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript Affimed N.V. (NASDAQ:AFMD ) Q2 2024 Earnings Conference Call September 5, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head, Investor Relations Shawn Leland - Chief Executive Officer Andreas…
globenewswire.com Affimed Reports Second Quarter 2024 Financial Results & Business Update MANNHEIM, Germany, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
seekingalpha.com Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts On 06/11/24, I published an article on Affimed focused on my belief the company's upcoming acimtamig update would be positive. It was, and Affimed's stock popped the next day. The stock has since…
benzinga.com Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
benzinga.com Earnings Scheduled For March 28, 2024 Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
benzinga.com Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.- benzinga.com Earnings Scheduled For November 14, 2023 Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
benzinga.com Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger…- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 149 companies reached new 52-week lows.
benzinga.com Earnings Scheduled For May 23, 2023 Companies Reporting Before The Bell • ATRenew (NYSE:RERE) is estimated to report quarterly earnings at $0.03 per share on revenue of $405.22 million.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 175 stocks hit new 52-week lows.
- benzinga.com Earnings Scheduled For March 23, 2023 Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 79 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 135 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday OnWednesday, 78 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday saw 196 companies set new 52-week lows.
- benzinga.com Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
- benzinga.com Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
- benzinga.com Earnings Scheduled For November 15, 2022 Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million.
- benzinga.com Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.